Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact

Commentary

  • 1,517 Articles
  • 0 Posts
  • ← Previous
  • 1
  • 2
  • 3
  • 4
  • …
  • 151
  • 152
  • Next →
Oncogene-induced DNA damage: cyclic AMP steps into the ring
James A. Fagin, John H. Petrini
James A. Fagin, John H. Petrini
Published September 28, 2020
Citation Information: J Clin Invest. 2020. https://doi.org/10.1172/JCI142237.
View: Text | PDF

Oncogene-induced DNA damage: cyclic AMP steps into the ring

  • Text
  • PDF
Abstract

Growth hormone–secreting (GH-secreting) pituitary tumors are driven by oncogenes that induce cAMP signaling. In this issue of the JCI, Ben-Shlomo et al. performed a whole-exome study of pituitary adenomas. GH-secreting tumors had a high frequency of whole chromosome or chromosome arm copy number alterations and were associated with an increase in the tumor protein p53 and the cyclin-dependent kinase inhibitor p21WAF1/CIP1, which are findings consistent with induction of a response to DNA damage. Further, treatment of mouse pituitary cells with cAMP pathway agonists in vitro and in vivo elicited biomarkers of DNA replication stress or double-strand breaks. The findings of Ben Shlomo et al. indicate that oncoproteins that drive constitutively high cAMP signaling pathway output in susceptible cell types can elicit DNA replication stress and may promote genomic instability.

Authors

James A. Fagin, John H. Petrini

×

Getting to the point in point-of-care diagnostics for tuberculosis
Elisa H. Ignatius, … , Keira A. Cohen, William R. Bishai
Elisa H. Ignatius, … , Keira A. Cohen, William R. Bishai
Published September 28, 2020
Citation Information: J Clin Invest. 2020. https://doi.org/10.1172/JCI142497.
View: Text | PDF

Getting to the point in point-of-care diagnostics for tuberculosis

  • Text
  • PDF
Abstract

Tuberculosis (TB) continues to affect over 10 million people per year worldwide. Despite advances in diagnosis, smear microscopy insufficiently detects pulmonary disease, with test result reporting taking longer than a day. While urine assays to detect the lipopolysaccharide lipoarabinomannan (LAM), present in mycobacterial cell walls, can provide results within minutes, the currently available assay has low sensitivity and its application is limited to patients with HIV suspected of having TB. In this issue of the JCI, Broger and Nicol et al. investigated 3 rapid urine tests in 372 ambulatory HIV-negative individuals suspected of having TB in South Africa and Peru. FujiLAM emerged as a 25-minute test to confirm TB diagnosis in the HIV-seronegative population. This study shows that FujiLAM has considerable potential to reshape the TB diagnostics landscape, making diagnosis and treatment in one office visit a reality for TB.

Authors

Elisa H. Ignatius, Keira A. Cohen, William R. Bishai

×

Corticosteroids, COVID-19 pneumonia and acute respiratory distress syndrome
Michael A. Matthay, Katherine D. Wick
Michael A. Matthay, Katherine D. Wick
Published September 25, 2020
Citation Information: J Clin Invest. 2020. https://doi.org/10.1172/JCI143331.
View: Text | PDF

Corticosteroids, COVID-19 pneumonia and acute respiratory distress syndrome

  • Text
  • PDF
Abstract

While corticosteroids dampen the dysregulated immune system and sometimes are prescribed as an adjunctive treatment for pneumonia, their effectiveness in the treatment of coronavirus 2019 (COVID-19) remains controversial. In this issue of the JCI, Liu and Zhang et al. evaluated corticosteroid treatment in more than 400 patients with severe COVID-19. The authors assessed subjects retrospectively for cardiac and liver injury, shock, ventilation, mortality, and viral clearance. Corticosteroids in severe COVID-19 related acute respiratory distress syndrome (ARDS) was associated with increased mortality and delayed viral clearance. Here, we consider how to reconcile the negative effects of corticosteroids revealed by Liu and Zhang et al. with the favorable effects (reduced mortality) that were described in the RECOVERY trial. We posit that treatment timing, dosage, and COVID-19 disease severity determine immune response and viral outcome. Patients with moderate-to-severe COVID-19 pneumonia are likely to benefit from moderate dose corticosteroid treatment when administered relatively late in the disease course.

Authors

Michael A. Matthay, Katherine D. Wick

×

Are T cells helpful for COVID-19: the relationship between response and risk
Diane E. Griffin
Diane E. Griffin
Published September 25, 2020
Citation Information: J Clin Invest. 2020. https://doi.org/10.1172/JCI142081.
View: Text | PDF

Are T cells helpful for COVID-19: the relationship between response and risk

  • Text
  • PDF
Abstract

The disease spectrum of coronavirus disease 2019 (COVID-19) ranges from no symptoms to multisystem failure and death. Characterization of virus-specific immune responses to severe acute respiratory coronavirus 2 (SARS-CoV-2) is key to understanding disease pathogenesis, but few studies have evaluated T cell immunity. In this issue of the JCI, Sattler et al. sampled blood from subjects with COVID-19 and analyzed the activation and function of virus antigen-specific CD4+ T cells. T cells that failed to respond to peptides from the membrane, spike or nucleocapsid proteins were more common in subjects who died. In those whose T cells had the capacity to respond, older patients with more co-morbidity had larger numbers of activated T cells compared with patients that had fewer risk factors, but these cells showed impaired IFN- production. This cross-sectional study relates activated T cell responses to patient risk factors and outcome. However, T cell response trajectory over the disease course remains an open question.

Authors

Diane E. Griffin

×

Insights into how innocuous foods or proteins deserving of immune ignorance can become allergens
Larry Borish
Larry Borish
Published September 21, 2020
Citation Information: J Clin Invest. 2020. https://doi.org/10.1172/JCI141950.
View: Text | PDF

Insights into how innocuous foods or proteins deserving of immune ignorance can become allergens

  • Text
  • PDF
Abstract

Allergic disorders include food allergy, allergic rhinitis, and certain forms of asthma resulting from the inappropriate development of immune responses to otherwise innocuous aeroallergens and foods. In this issue of the JCI, Thouvenot and Roitel et al. explore transcription infidelity as a mechanism that underlies the ability of these benign proteins to become allergens. Some foods and bioaerosols that produce allergies have RNA polymerase with a propensity to generate RNA gaps, thereby causing translational frameshifts. These frameshifts often create cationic carboxy-terminus residues that replace hydrophobic amino acids and have enhanced MHC binding, resulting in the tendency to provoke immune responses. IgE antibody responses initiated by these variant transcripts can later lead to IgE against the native molecule and also explain how anaphylaxis may occur in individuals who lacked specific IgE when tested using native protein reagents. This study has the potential to transform the diagnosis and treatment of allergic disorders.

Authors

Larry Borish

×

The yin and yang of retinoic acid signaling in kidney diseases
Qingqing Wei, Zheng Dong
Qingqing Wei, Zheng Dong
Published September 14, 2020
Citation Information: J Clin Invest. 2020. https://doi.org/10.1172/JCI141712.
View: Text | PDF

The yin and yang of retinoic acid signaling in kidney diseases

  • Text
  • PDF
Abstract

Retinoic acid (RA) signaling is involved in various physiological and pathological conditions, including development, tumorigenesis, inflammation, and tissue damage and repair. In kidneys, the beneficial effect of RA has been reported in multiple disease models, such as glomerulosclerosis, renal fibrosis, and acute kidney injury. In this issue of the JCI, Chen et al. report a pathway activated by RA signaling that is mediated by the retinoic acid receptor responder protein 1 (RARRES1). Specifically, RARRES1, which is proteolytically cleaved to release the extracellular domain, was endocytosed by podocytes to induce apoptosis and glomerular dysfunction kidney disease. These findings unveil the contrasting aspects, a Janus face, of RA signaling that may guide its therapeutic use.

Authors

Qingqing Wei, Zheng Dong

×

NK cells in the tumor microenvironment and thioredoxin activity
Theresa L. Whiteside
Theresa L. Whiteside
Published September 14, 2020
Citation Information: J Clin Invest. 2020. https://doi.org/10.1172/JCI141460.
View: Text | PDF

NK cells in the tumor microenvironment and thioredoxin activity

  • Text
  • PDF
Abstract

NK cells are responsible for defense against viral infections and cancer. Although activated NK cells are armed to combat tumors, the tumor microenvironment (TME) contains ROS, which suppress NK cell antitumor activity. In this issue of the JCI, Yang, Neo, and colleagues explored NK cell resistance to oxidative stress in vitro and in human non–small-cell lung cancer (NSCLC). High surface thiol density and elevated expression of the ROS scavenger thioredoxin (Trx1) protected NK cells from ROS. Trx1 and thiol levels were higher in IL-15– than in IL-2–primed NK cells. Tumor-infiltrating Trx1+ NK cells were present in patients with NSCLC with elevated ROS levels in the tumor. Smokers scored higher for the ROS signature, which predicted poor prognosis, compared with nonsmokers. This study explains how activated NK cells survive in the ROS-rich TME and suggests that smokers with lung cancer may benefit from therapies using IL-15–primed NK cells.

Authors

Theresa L. Whiteside

×

Complement and coagulation: key triggers of COVID-19-induced multiorgan pathology
Berhane Ghebrehiwet, Ellinor I. Peerschke
Berhane Ghebrehiwet, Ellinor I. Peerschke
Published September 14, 2020
Citation Information: J Clin Invest. 2020. https://doi.org/10.1172/JCI142780.
View: Text | PDF

Complement and coagulation: key triggers of COVID-19-induced multiorgan pathology

  • Text
  • PDF
Abstract

In a stunningly short period of time, the unexpected coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has turned the unprepared world topsy-turvy. Although the rapidity with which the virus struck was indeed overwhelming, scientists throughout the world have also been up to the task of deciphering the mechanisms by which SARS-CoV-2 induces the multisystem- and multiorgan-inflammatory response that, collectively, contribute to the high mortality rate in affected individuals. In this issue of the JCI, Skendros et al., is one such team who report that the complement system plays a substantial role in creating the hyper-inflammation and thrombotic microangiopathy that appear to contribute to the severity of COVID-19. In support of the hypothesis that the complement system along with neutrophils and platelets contributes to COVID-19, the authors presented empirical evidence showing that treatment with the complement inhibitor, compstatin Cp-40, inhibited the expression of tissue factor in neutrophils. These results confirm that the complement axis plays a critical role and suggests that targeted therapy using complement inhibitors is a potential therapeutic option to treat COVID-19 induced inflammation.

Authors

Berhane Ghebrehiwet, Ellinor I. Peerschke

×

Caring for patients in a new pandemic: the necessity and challenges of observational research
David L. Thomas
David L. Thomas
Published September 9, 2020
Citation Information: J Clin Invest. 2020. https://doi.org/10.1172/JCI143292.
View: Text | PDF

Caring for patients in a new pandemic: the necessity and challenges of observational research

  • Text
  • PDF
Abstract

People with COVID-19 can develop pneumonia and severe inflammatory response with excessive cytokine release known as the cytokine storm. The Janus kinase inhibitor baricitinib used to treat rheumatoid arthritis reduces inflammation by modifying the cytokine pathway. In this issue of the JCI, Bronte and Ugel et al. performed an observational longitudinal study to evaluated the use of baricitinib in 20 patients with COVID-19. Treated subjects showed reduced levels of plasma interleukin (IL)-6, tumor necrosis factor (TNF), IL-1β and phosphorylated STAT3 and swift lymphocyte restoration. Notably, these patients had a dramatically favorable clinical outcome. While bias can plague uncontrolled research, this study has biological credibility and warrants randomized control studies.

Authors

David L. Thomas

×

Expanding mechanistic insights into the pathogenesis of idiopathic CD4+ T cell lymphocytopenia
Jose S. Campos, … , Sarah E. Henrickson, Roshini S. Abraham
Jose S. Campos, … , Sarah E. Henrickson, Roshini S. Abraham
Published August 31, 2020
Citation Information: J Clin Invest. 2020. https://doi.org/10.1172/JCI141717.
View: Text | PDF

Expanding mechanistic insights into the pathogenesis of idiopathic CD4+ T cell lymphocytopenia

  • Text
  • PDF
Abstract

Idiopathic CD4+ T cell lymphocytopenia (ICL) is a heterogeneous syndrome presenting with persistent CD4+ T cell lymphopenia of unknown origin, and opportunistic infections in some patients. The underlying pathogenesis and appropriate management remain understudied. In this issue of the JCI, Perez-Diez and Wong et al. assessed the prevalence of autoantibodies from the sera of 51 adult ICL patients (out of a cohort of 72). Some patients showed high levels of IgG and IgM autoantibodies against numerous autoantigens, and some autoantibodies were specific for lymphocytes. The researchers implicate these autoantibodies as a possible pathogenic mechanism responsible for the reduction in circulating CD4+ T cells. This study goes beyond defining a mechanism in a complex, poorly defined disease; it also brings a renewed focus on ICL that will likely result in improved diagnostic evaluation and treatment.

Authors

Jose S. Campos, Sarah E. Henrickson, Roshini S. Abraham

×
  • ← Previous
  • 1
  • 2
  • 3
  • 4
  • …
  • 151
  • 152
  • Next →

No posts were found with this tag.

Advertisement
Follow JCI:
Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts